Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry by Navaglia, Filippo et al.
Clin Chem Lab Med 2009;47(6):713–723  2009 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2009.158 2009/567
Article in press - uncorrected proof
Pancreatic cancer biomarkers discovery by surface-enhanced
laser desorption and ionization time-of-flight mass
spectrometry1)
Filippo Navaglia1, Paola Fogar2, Daniela Basso1,
Eliana Greco1, Andrea Padoan1, Loris
Tonidandel3, Elisa Fadi1, Carlo-Federico
Zambon2, Dania Bozzato1, Stefania Moz1,
Roberta Seraglia3, Sergio Pedrazzoli2 and
Mario Plebani1,*
1 Department of Laboratory Medicine, University of
Padova, Padova, Italy
2 Department of Medical and Surgical Sciences,
University of Padova, Padova, Italy
3 CNR-ISTM, Padova, Italy
Abstract
Background: Surface-enhanced laser desorption and
ionization time-of-flight mass spectrometry (SELDI-
TOF/MS), a laboratory-friendly technique, is used to
identify biomarkers for cancer. The aim of the present
study was to explore the application of SELDI proteo-
mic patterns in serum for distinguishing between
cases of pancreatic cancer, chronic pancreatitis, type
2 diabetes mellitus and healthy controls.
Methods: Sera from 12 healthy controls, 24 patients
with type 2 diabetes mellitus, 126 with pancreatic can-
cer, including 84 with diabetes, and 61 with chronic
pancreatitis, 32 of which were diabetics, were ana-
lyzed using SELDI-TOF/MS. Spectra (IMAC-30) were
clustered and classified using Biomarker Wizard and
Biomarker Pattern software.
Results: Two decision tree classification algorithms,
one with and one without CA 19-9, were constructed.
In the absence of CA 19-9, the splitting protein peaks
were: m/z 1526, 1211, and 3519; when CA 19-9 was
used in the analysis, it replaced the m/z 3519 splitter.
The two algorithms performed equally for classifying
patients. A classification tree that considered diabetic
patients only was constructed; the main splitters
were: 1211, CA 19-9, 7903, 3359, 1802. With this algo-
rithm, 100% of patients with type 2 diabetes mellitus,
97% with chronic pancreatitis and 77% of patients
with pancreatic cancer were correctly classified. SEL-
DI-TOF/MS features improved the diagnostic accuracy
of CA 19-9 (AUCs0.883 for CA 19-9; AUCs0.935 for
CA 19-9 and SELDI-TOF/MS features combined).
1) The article is based on a contribution at the 4th Santorini
Conference Biologie Prospective, September 21–23, 2008.
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Conclusions: SELDI-TOF/MS allows identification of
new peptides which, in addition to CA 19-9, enable
the correct classification of the vast majority of
patients with pancreatic cancer, which can be distin-
guished from patients with chronic pancreatitis or
type 2 diabetes mellitus.
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Introduction
Pancreatic adenocarcinoma has a very unfavorable
prognosis with overall 5 years survival not exceeding
5%. In 2008, pancreatic adenocarcinoma accounted
for over an estimated 34,000 deaths in the USA alone
(1). This high mortality rate is primarily attributed to
late diagnosis and to lack of effective chemotherapy.
Currently, surgery is the only curative approach avail-
able for this tumor, although a limited number of
patients, ;20%, have resectable tumor at diagnosis
(2). Improvement in survival might be obtained by
increasing the number of candidates for curative sur-
gery, and this objective could be accomplished by
establishing a diagnosis as early as possible. The
identification of patients affected by early pancreatic
adenocarcinoma cannot be based exclusively on
symptoms which, in the majority of the cases, are
unremarkable and similar to those of functional gas-
trointestinal disorders including dyspepsia, abdomi-
nal discomfort, and decreased appetite. Clinical
features, such as jaundice or weight loss, which usu-
ally occur at more advanced stages, compromise the
efficacy of curative surgery.
One major clinical feature of pancreatic cancer is
early onset diabetes mellitus or reduced glucose tol-
erance, diagnosed in more than 80% of patients (3–5).
This is thought to occur as a consequence of release
of low molecular weight diabetogenic peptides by
cancer cells (6, 7). The identification of cancer-asso-
ciated diabetogenic biomarkers in sera may be
extremely useful in identifying patients with newly
diagnosed diabetes mellitus as a consequence of
underlying pancreatic cancer.
Of the numerous biomarkers studied in patients
with pancreatic cancer, the only one currently rec-
ommended in clinical practice is serum CA 19-9. How-
ever, this marker is of little utility in establishing an
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Table 1 Clinical characteristics of the 4 subjects’ groups included in the study.
Pancreatic Chronic Type 2 Healthy
cancer pancreatitis diabetes controls
mellitus
Total number of cases 126 61 24 12
Gender (cases)
Males 72 47 12 2
Females 54 14 12 10
Statistics x2s18, p-0.001
Age (years)
Mean 67 56 55 41
Median 69 56 56 39
Range 43–86 18–81 26–78 29–52
25th percentile 60 50 44 35
75th percentile 75 66 71 49
Statistics Kruskal-Wallis test: x2s60, p-0.001
Comorbidity (cases no.)
Diabetes mellitus 79 30 24 0
RGT 12 3 0 0
Normal 35 28 0 12
Statistics x2s46, p-0.001
CA 19-9 (kU/L)
Mean 25,133 29 13 14
Median 235 11 11 11
Range 1–1.3=106 1–307 0–39 2–32
25th percentile 90 6 6 8
75th percentile 972 30 19 21
Statistics Kruskal-Wallis test: x2s86, p-0.001
RGT, reduced glucose tolerance.
early diagnosis (8). In fact, circulating concentrations
of this marker parallel tumor stage and may be
altered in cases of biliary obstruction (9). This makes
it difficult to establish whether an increased CA 19-9
concentration in a jaundiced patient is due to the
presence of pancreatic malignancy, or due to benign
biliary obstruction. Thus, new diagnostic modalities
that enable early detection of pancreatic cancer in a
safe, non-invasive and cost-effective way are urgently
needed.
The discovery of new cancer biomarkers has
received renewed interest in recent years as a result
of advances in the field of proteomics. The proteome
is believed to hold secrets to many patho-physiolog-
ical alterations, including those associated with can-
cer (10–12). Serum or plasma are suitable materials
for studying the proteome in the attempt to identify
new cancer biomarkers. However, proteins present in
high abundance such as albumin and immunoglobu-
lins might obscure the identification of potentially
new biomarkers that are present in low abundance
(13, 14). Sera from patients with cancer, including that
from patients with pancreatic cancer, usually have a
rich protein profile in the low molecular weight range
(-15,000 Da) (15–21). The enrichment of low molec-
ular weight peptides in sera from cancer patients may
occur as a consequence of direct production by the
tumor, or it may be due to expression of a biological
cascade of enzymatically-generated and proteolytical-
ly-cleaved biomarker fragments. Since major serum
proteins have molecular weights much higher than
15,000 Da, their interference might be limited when
the search for new biomarkers is focused on proteins
of low molecular weight. Study of the low molecular
weight range serum proteome can be performed
using different mass spectrometry (MS) based proteo-
mic techniques that measure the mass to charge
(m/z) ratio of ionizing particles including small mole-
cules, protein/peptides, and fatty acids (12). MS tech-
niques such as matrix assisted laser desorption/
ionization-time-of-flight (MALDI-TOF), electrospray
ionization (ESI), QSTAR-TOF and surface-enhanced
laser desorption and ionization (SELDI)-TOF may be
employed to study the serum proteome, including
low molecular weight peptides. SELDI-TOF/MS has an
advantage over the other procedures in that it is a
high throughput technique which facilitates the iden-
tification of multiple biomarkers (10, 12, 14). In addi-
tion, it is considered one of the most useful tools
available for the analysis of serum or plasma. Crude
samples can be applied directly to an affinity surface,
and highly abundant proteins are cleaned from
unbound proteins and other interfering substances by
repeated washing. As a result of these characteristics,
SELDI-TOF/MS is a laboratory friendly, rapid proce-
dure suitable for analysis of large numbers of
samples.
The aim of the present study was to identify, using
SELDI-TOF/MS, serum specific peptide biomarkers
able to differentiate patients with pancreatic adeno-
carcinoma from those with diabetes mellitus or
chronic pancreatitis, and from healthy controls.
Materials and methods
Patients and samples
Two hundred and twenty-three subjects participated in the
study and their clinical characteristics are detailed in Table 1.
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For all cases, the diagnosis of pancreatic adenocarcinoma
was confirmed histologically on surgical specimens. Tumor
stages were: IB (9 cases), IIA (11), IIB (37), III (25), and IV (44).
Of the 126 patients with pancreatic cancer, 94 had a median
follow-up of 11.5 (range 1–131) months. Chronic pancreatitis
was diagnosed based on positive findings from at least two
of the following: plain abdomen X-ray for pancreatic calcifi-
cations; pancreatic ultrasonography; computed axial tomo-
graphy; endoscopic retrograde pancreatography. Diagnosis
of diabetes mellitus was based upon a fasting plasma glu-
cose concentration )7.0 mmol/L on two separate days, or a
2-h post-load glucose concentration above 11.1 mmol/L dur-
ing an oral glucose tolerance test (OGTT). Patients were con-
sidered to have reduced glucose tolerance if their fasting
plasma glucose levels were above 5.6 mmol/L, but below
7.0 mmol/L, or 2-h values during an OGTT were above
7.8 mmol/L, but below 11.1 mmol/L (22). Using these criteria,
overt diabetes mellitus and reduced glucose tolerance were
diagnosed in a subset of patients with pancreatic cancer and
chronic pancreatitis (Table 1). A fasting blood sample was
obtained from all subjects. Each sample was allowed to clot
and then centrifuged at 4000=g for 5 min. The sera was
collected and stored at –208C until examination.
SELDI-TOF/MS analysis
Ten microliter of each serum sample was applied to IMAC-
30 ProteinChip array surface (Bio-Rad Laboratories, Hercu-
les, CA, USA), a metal affinity capture. Following a coupling
reaction with copper (5 mL CuSO4 0.1 M surface treatment
for 10 min at room temperature), samples were washed,
treated with sodium acetate (0.1 M pH 4.0), re-washed and
treated with binding buffer (PBS 50 mM, pH 7.2). Samples
were then incubated in a humidity chamber for 1 h at room
temperature. Following three more washes with the binding
buffer and two washes with distilled water, the arrays were
air-dried and applied to the matrix w1.5 mL a-Cyano-4-
hydroxycinnamic acid (HCCA) in 50% acetonitrile/0.1% TFAx.
Mass spectra were generated with SELDI-TOF/MS using a
ProteinChip reader PBSIIc (Bio-Rad Laboratories). The instru-
ment was set to measure in the range between m/z 1000 and
m/z 15,000. The laser intensity was 120 and detector sensi-
tivity was 6. External calibration of the instrument was per-
formed using the All-in-1 peptide molecular mass standard
(Bio-Rad Laboratories). All samples were normalized accord-
ing to the total ion current mass-to-charge ratio (m/z)
between 1000 and 15,000 Da, and qualified mass peaks (sig-
nal-to-noise ratio )5) with m/z between 1000 and 15,000 Da
automatically detected. A peak threshold of 5% was selected
for all spectra. A second-pass peak selection was performed
by choosing a mass window within 0.3% (signal-to-noise
ratio )2), and estimated peaks were added.
Quantitative analysis of human CA 19-9
Measurement of CA 19-9 serum concentrations were per-
formed using a chemiluminescence procedure (ADVIA Cen-
taur CP Immunoassay System, Siemens, Deerfield, IL,
USA). Briefly, the ADVIA Centaur CA 19-9 assay, a fully auto-
mated two-step sandwich immunoassay using direct chem-
iluminescent technology, eliminates any high dose hook
effect. A single monoclonal antibody (116-NS-19-9) is cou-
pled to paramagnetic particles (Solid Phase) and labeled
with acridinium ester in the Lite Reagent. After washing, the
sample, first incubated with the Solid Phase, is incubated
with the Lite Reagent, which develops a chemiluminescent
signal directly correlated with the amount of CA 19-9 in the
serum.
Protein identification by MALDI-TOF/MS analysis
Serum samples, diluted 1:2 (v:v) in saline solution, were cen-
trifuged for 1 h at 6200=g using Centricon tubes (Millipore,
Billerica, MA, USA) at a 50,000 Da cut-off, and for 20 min at
6200=g using Centricon tubes at a 10,000 cut-off. Prior to
MALDI-TOF/MS analysis, the filtrates were diluted 1:10 with
water containing 0.1% TFA, then desalted and purified using
ZipTip C18 pipette tips (Millipore), following the manufactu-
rer’s instructions. The low molecular weight peptides were
eluted with a solution of HCCA (2.5 g/L H2O/Acetonitrile 50/
50 v:v with 0.1% TFA). One microliter of the elution mixture
was deposited on the stainless steel sample holder, allowed
to dry and then introduced into the mass spectrometer.
MALDI-TOF/MS analysis was performed using a 4800 MAL-
DI-TOF-TOF instrument (Applied Biosystems, Foster City, CA,
USA), operating in reflectron positive ion mode. Ions were
formed with a pulsed UV laser beam (ls337 nm). The fol-
lowing experimental conditions were used: source 1: 20 kV;
grid 1: 16 kV; mirror 2: 20.520 kV. External mass calibration
was performed using Calibration Mixture 2 of Sequazyme
Peptide Mass Standards Kit (Applied Biosystems). MS/MS
analysis were performed by accelerating the precursor ions
to 8 kV, and MS/MS spectra were acquired using 2 kV colli-
sion energy with CID gas (air) at a pressure of 1.5=10–6 torr.
Statistical analysis
ProteinChip Software, version 3.2.1, and its Biomarker Wiz-
ard utility 3.1 (Bio-Rad Laboratories) were used to collect,
normalize and export instrument data. Student’s t-test for
unpaired data, one-way ANOVA, Bonferroni’s test for pair-
wise comparisons and Cox regression analysis were per-
formed using SPSS statistical software (version 9.0; Chicago,
IL, USA). Biomarker Patterns Software (Bio-Rad Laborato-
ries) was used to construct decision trees. This software
allows construction of trees using a CART methodology that
consists of binary recursive partitioning (23). This process
iterates a binary split. Every parent node is split into two
child nodes with a recursive algorithm, treating each child
node as a parent. Ten-fold cross-validation was used. The
Biomarker Patterns Software allows a receiver operating
characteristics (ROC) curve to be obtained from the classifi-
cation tree. Each point of the curve represents sensitivity and
1-specificity, obtained by considering one terminal node, two
terminal nodes, three terminal nodes, and so on, until one
less the total number of terminal nodes is reached (23).
Results
SELDI-TOF/MS disease associated features
Following the analysis of all spectra, 219 peak clusters
were identified with an m/z ratio ranging from a min-
imum of 1007 to a maximum of 9255. This range cov-
ered the low molecular weight range of the human
serum proteome. Univariate analysis revealed that
the peak intensities of the four patient groups studied
were significantly different for 165/219 features. Some
features were correlated with type 2 diabetes mellitus,
while others were found in abundance primarily in
patients with pancreatic cancer or chronic pancrea-
titis. Several features were frequently altered in all
patients when compared with controls (Table 2 and
Supplementary Table 1). Of the 12 features associated
with chronic pancreatitis, 10 had an m/z within the
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Table 2 Pancreatic cancer associated SELDI-TOF/MS features.
m/z CS PC CP DM One-way ANOVA
Features associated with pancreatic cancer
1542 4.8"0.5 24.5"1.7a 17.4"2.4 18.1"2.2 Fs6.0, p-0.05
1637 1.9"0.3 13.3"0.9a 8.4"0.9 8.6"0.8 Fs10.3, p-0.001
1802 1.9"0.5 19.6"1.3b 11.7"1.7 8.7"0.9 Fs12.3, p-0.001
1805 0.7"0.3 18.2"1.4a,c 11.4"1.2 10.7"2.5 Fs9.6, p-0.001
1916 3.0"1.2 12.9"0.9a 9.8"1.1 10.2"1.5 Fs5.6, p-0.01
1977 6.6"0.9 12.7"1.4c 4.4"0.8 8.7"1.4 Fs6.2, p-0.001
2140 1.2"0.3 8.0"0.8a 6.0"1.0 6.1"0.9 Fs3.3, p-0.05
2582 1.1"0.4 4.4"0.4b 2.4"0.3 1.8"0.4 Fs7.4, p-0.001
2878 1.1"0.1 5.3"0.4a,c 3.4"0.4 4.0"0.4 Fs6.7, p-0.001
3519 0.4"0.1 3.1"0.3a,c 1.6"0.3 2.4"0.3 Fs6.6, p-0.01
3756 1.6"0.5 8.4"0.8a,d 5.8"0.8 0.9"0.1 Fs8.6, p-0.01
4058 2.2"0.2 10.9"0.9a 7.2"0.9 7.8"1.7 Fs5.0, p-0.01
4265 5.2"0.9 12.2"1.0a,d 6.5"0.5 4.8"0.6 Fs9.2, p-0.001
The results of the univariate analysis (one-way ANOVA) are reported. The following groups were considered: healthy controls
(CS), pancreatic cancer (PC), chronic pancreatitis (CP) and type 2 diabetes mellitus (DM). Mean"standard error (SE) of peak
intensity for each group is reported. Bonferroni’s test for pairwise comparisons: awith respect to controls; bwith respect to all
the others; cwith respect to chronic pancreatitis; dwith respect to type 2 diabetes mellitus.
Figure 1 SELDI-TOF/MS spectra obtained from one patient with chronic pancreatitis (A), one with pancreatic cancer (B), one
with type 2 diabetes mellitus (C) and one healthy control (panel D).
m/z values are reported on the x-axis, and peak intensities on the y-axis.
range 2000–3000. Nineteen of the 24 features asso-
ciated with type 2 diabetes had an m/z within the
range 1000–2000. Although no feature specific for
pancreatic cancer was identified, some features were
found in greater abundance in patients with tumors,
and 4/13 patients had an m/z over 3000. Figure 1 illus-
trates a typical mass spectra from a patient with pan-
creatic cancer, a patient with chronic pancreatitis, one
with type 2 diabetes mellitus and a healthy control.
The 219 features that were identified were then used
to construct the decision classification tree algorithm
to identify clusters of features allowing patients with
pancreatic cancer to be discriminated from patients
with chronic pancreatitis, those with type 2 diabetes
mellitus, and healthy controls. The model with the
highest classification accuracy was constructed using
three features (m/z 1526, 1211 and 3519) to generate
four terminal nodes (Figure 2). According to the tree
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Figure 2 Classification algorithms obtained using SELDI-TOF/MS features.
Class 1, chronic pancreatitis; class 2, pancreatic cancer; class 3, healthy controls; class 4, type 2 diabetes mellitus.
classification model, if an unknown sample had an
m/z of 1526 with a peak intensity of )40,188, it was
placed in terminal node 4 and classified as a healthy
control (percentage of correct classifications100);
otherwise it was placed in the left branch node. The
cases in the left branch node were re-classified
according to the peak intensity of the second main
splitter, at m/z 1211. If the intensity was )8.37, sam-
ples were placed in terminal node 3 and considered
type 2 diabetes mellitus (percentage of correct clas-
sifications72.7). However, if the intensity was F8.37,
they were placed in the left branch and further sub-
divided on the basis of the intensity of the third main
splitter at m/z 3519. If the latter peak intensity was
)2.196, cases were placed in terminal node 2 and
classified as pancreatic cancer (percentage of correct
classifications88.9); otherwise, they were placed in
the terminal node 1 and classified as chronic pancre-
atitis (percentage of correct classifications49.5). The
overall accuracy of this classification tree was 69.9%.
Comparison of SELDI-TOF/MS disease associated
features with CA 19-9
To improve the detection rate, serum CA 19-9 con-
centrations were measured in all individuals who had
adequate residual sample for analysis (12 healthy
controls, 24 type 2 diabetes mellitus patients, 42
patients with chronic pancreatitis, and 114 with pan-
creatic cancer). This biomarker was used together
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Figure 3 Receiver operating characteristic (ROC) curves and
areas under the curves (AUC) showing the discriminating
capacity of SELDI-TOF/MS classifiers and CA 19-9 individu-
ally and combined, considering only patients with diabetes
mellitus (24 type 2 diabetes mellitus, 29 chronic pancreatitis,
73 pancreatic cancer).
with the 219 SELDI-TOF/MS features to construct
another decision classification tree. The best model
obtained confirmed the two SELDI-TOF/MS main
splitters at m/z 1526 and m/z 1211. The third splitter
(m/z 3519) was replaced by CA 19-9 with a discri-
minant value of 111 kU/L. Combining CA 19-9 and
SELDI-TOF/MS classifiers showed a higher percent-
age of patients with pancreatic cancer or chronic pan-
creatitis being classified correctly (96.4% of pancreatic
cancer cases in terminal node 2 and 56.8% of chronic
pancreatitis cases in terminal node 1), with an overall
accuracy of 76.2% being achieved. Using the estab-
lished cut-off of 37 kU/L, CA 19-9 alone had a sensi-
tivity of 82.8% in diagnosing pancreatic cancer, a
specificity of 100% with respect to healthy controls,
83.3% with respect to chronic pancreatitis and 95.5%
with respect to type 2 diabetes mellitus. Its overall
accuracy was 85.7%. SELDI-TOF/MS classifiers did not
improve the overall diagnostic performance of CA 19-
9 alone in diagnosing patients with pancreatic cancer
warea under the ROC curve (AUC)s0.889 for CA 19-9;
AUCs0.812 for SELDI-TOF/MS features; AUCs0.860
for CA 19-9 and SELDI-TOF/MS features combinedx.
Therefore, all subsequent analyses included CA 19-9.
SELDI-TOF/MS disease associated features and CA
19-9 in patients with diabetes mellitus
One of the objectives of the present study was to
identify new biomarkers that would allow more accu-
rate distinctions to be made between patients with
diabetes mellitus with and without pancreatic cancer.
We selected only cases with diabetes mellitus and
available CA 19-9 levels. This gave us 24 patients with
type 2 diabetes mellitus, 29 with chronic pancreatitis
and 73 with pancreatic cancer. The diagnostic efficacy
of CA 19-9 alone and SELDI-TOF/MS classifiers alone
was similar, but when both parameters were com-
bined, significant improvement was achieved in dis-
criminating between pancreatic cancer and chronic
pancreatitis or patients with type 2 diabetes mellitus
(Figure 3). The algorithm obtained by combining SEL-
DI-TOF/MS features and CA 19-9 (Figure 4) allowed
correct classification of almost all cases with type 2
diabetes mellitus (100% correct classification). How-
ever, it did not allow us to obtain definite discrimi-
nation of pancreatic cancer (76.7% correct
classification) and chronic pancreatitis cases (96.6%
correct classification).
Metastases and survival of pancreatic cancer
patients: SELDI-TOF/MS features and CA 19-9
The presence or absence of metastases was consid-
ered in pancreatic cancer cases in order to construct
a new algorithm (Figure 5). CA 19-9 was selected in
this case as the main splitter, together with the fea-
ture at m/z 3199. Forty of the 74 cases without meta-
stases were allocated to terminal node 1 (absence of
metastases) on the basis of CA 19-9 concentrations
F220.6 kU/L. For the 66 cases with CA 19-9 concen-
trations )220.6 kU/L, the second splitter (m/z 3199)
allowed the identification of metastases, with a sen-
sitivity of 100% and a specificity of 35%.
In order to investigate whether SELDI-TOF/MS fea-
tures were predictive of survival in patients with pan-
creatic cancer, an analysis was made of the 94
patients who had follow-up following diagnosis.
Patients were subdivided into two groups on the basis
of survival: short-term (F18 months) and long-term
survivors ()18 months). Six SELDI-TOF/MS features
significantly correlated with survival (Table 3), which
did not correlate with CA 19-9 (ts1.5, p: ns). We
selected the six significant features reported in Table
3 as covariates in order to perform Cox regression
analysis, patients being stratified on the basis of
tumor stage. Only three features were confirmed to
be significantly correlated with survival, those at m/z
1805, 2054 and 2878.
MALDI-TOF/MS analysis
Sera with a high abundance of features at m/z 1526,
1211 and 3519, the main splitters of the diagnostic tree
algorithm, were selected and analyzed using MALDI-
TOF/MS to confirm their presence in the samples.
Since SELDI-TOF/MS has a lower mass resolution
compared with MALDI-TOF/MS, a perfect mass cor-
respondence between the m/z values of ions detected
by the two analytical instruments cannot be expected.
In MALDI-TOF/MS spectra, the ion at m/z 1526 was
not detected, while the ionic species at m/z 1211 and
m/z 3519 (corresponding to MALDI-TOF/MS value:
m/z 3522.2080) were detected with a very low abun-
dance (Figure 6, panel A). The only MS/MS spectrum
useful for obtaining peptide sequence information was
achieved for the m/z 3522.2080 ionic specie (Figure 6,
panel B). A match search using Protein Prospector
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Figure 4 Classification algorithm obtained using SELDI-TOF/MS features and CA 19-9 combined, considering only patients
with diabetes (24 type 2 diabetes mellitus, 29 chronic pancreatitis, 73 pancreatic cancer).
Class 1, chronic pancreatitis; class 2, pancreatic cancer; class 4, type 2 diabetes mellitus.
version 4.27.2 in the database Swiss Prot 2008.06.10
was performed. A series of possible putative protein
fragments were identified; among them, the most reli-
able was the deamidated fragment 458–493 of Multi-
ple Epidermal Growth Factor-like domain 6 precursor
wN(Deamidated)CSFSCSCQN(Deamidated)GGTCDSV-
TGACRCPPGVSGTN(Deamidated)CEDGC; NCBI
accession number: O75095x (m/z 3522.2082; number
of matching fragmentss27/36; probability score
s21.4). Few peaks due to the main sequence ions
(i.e., y- and b-series) were present in the MS/MS spec-
trum of this peptide. The majority of the peaks origi-
nated from internal cleavages. This pattern can be
ascribed to the presence of three deamidated N resi-
dues. Details on fragments are reported in Supple-
mentary Table 2.
Discussion
In the present study, the SELDI-TOF/MS proteomic
approach was used to identify new low-molecular
weight serum biomarkers for the diagnosis of pancre-
atic cancer. Previous studies focusing on this issue
were conducted considering only patients with pan-
creatic cancer and controls (16, 24), or had controls
that included few patients with chronic or acute pan-
creatitis (18, 21, 25). As yet, no studies are available
that have compared the serum proteomic profile of
patients with pancreatic cancer with those having
type 2 diabetes mellitus. However, it is important to
consider patients with both chronic pancreatitis and
type 2 diabetes mellitus because: 1) in some cases,
the clinical picture of chronic pancreatitis mimics that
720 Navaglia et al.: SELDI-TOF/MS in pancreatic cancer
Article in press - uncorrected proof
Figure 5 Classification algorithm obtained using SELDI-
TOF/MS features and CA 19-9 combined to discriminate
between pancreatic cancer patients with (class 1) and those
without (class 0) distant metastases.
114/126 pancreatic cancer patients were available for analy-
sis, since in 12 cases CA 19-9 values were unavailable due
to lack of material.
Table 3 SELDI-TOF/MS features and pancreatic cancer patients’ survival.
Features, Long survivors Short survivors Univariate Multivariate
m/z )18 months F18 months Student’s t-test Cox regression analysis
Mean"SEM Mean"SEM t p-Value Exp (B) Lower Upper p-Value
1805 27.0"3.4 14.1"1.4 4.1 -0.001 0.98 0.96 1.00 -0.05
1887 6.6"0.8 10.0"0.9 2.7 -0.01 1.00 0.96 1.05 ns
2054 4.0"0.4 6.4"0.6 3.2 -0.01 1.09 1.03 1.16 -0.01
2815 8.4"1.6 14.7"2.0 2.5 -0.05 1.00 0.97 1.02 ns
2878 4.1"0.7 6.1"0.6 2.2 -0.05 1.10 1.03 1.18 -0.01
4100 4.3"0.9 2.5"0.2 2.9 -0.01 1.02 0.91 1.13 ns
The results of univariate (Student’s t-test for unpaired data) and multivariate (Cox regression analysis) statistical analysis are
shown. The multivariate test included term for tumor stage. ns, not significant; SEM, standard error of the mean.
of pancreatic cancer, and vice versa; 2) chronic pan-
creatitis is considered a risk factor for pancreatic can-
cer, the onset of which should be identified as early
as possible (26); 3) in many cases, diabetes mellitus,
frequently associated with pancreatic cancer, is the
presenting symptom of the latter (3–5). Since SELDI-
TOF/MS provides the opportunity to analyze all the
low molecular weight serum proteome (27), we
obtained accurate sera profiles within the range of
m/z 1000–10,000. Of the numerous features identified
using this range, many were present only occasion-
ally. Although their diagnostic and/or pathophysio-
logical significance cannot be ruled out ‘‘a priori’’, we
decided to analyze only those features detectable in
more than 5% of spectra. With this limit, a total of 219
features were entered in the analysis of data. For each
feature, the abundance, which grossly indicates the
amount of a given m/z feature, was considered. With
univariate analysis, some diabetes-, chronic pancrea-
titis- and pancreatic cancer-associated features
emerged. In addition, many features that are com-
monly altered in diseased patients were seen. Many
features associated with pancreatic cancer were not
specifically correlated with this tumor type, but were
also present in chronic pancreatitis. This finding is in
agreement with results obtained by Kojima et al. (21).
These investigators used MALDI-TOF/MS to analyze
sera and urine from a series of patients comparable
to ours, and found no tumor-specific feature. One of
the features identified by these authors as increased
in the urine samples of patients with both pancreatic
cancer and chronic pancreatitis compared to healthy
controls (m/z 2193), was detected by us in the sera of
the same groups of patients. However, we observed
the opposite findings: the mean abundance was lower
in patients than in healthy controls. Other differen-
tially expressed features detected in the present
series, particularly those at m/z 4277, 3756 and 4058,
were identical or very close to features identified by
other authors (16). These other investigators not only
selected similar patient series and used the SELDI
technique, but also employed the same protein chip
as that used by us (IMAC30).
The data described above support the concept that
the reproducibility of MS in different laboratories calls
for similar series of patients to be analyzed using
standardized analytical procedures. One feature
believed to be associated with pancreatic cancer, m/z
4058, was found by us to be very similar to a feature
described by Scarlett et al. (28); concentrations being
higher in cyst fluid from three patients with pancreatic
cancer compared with cyst fluid obtained from seven
patients who were carcinoma-free. This finding,
potentially of clinical relevance, supports the m/z 4058
feature as being a product of pancreatic cancer that
can be detected in serum. However, for the vast
majority of cancer associated features identified in
previous studies analyzing tissue samples or pancre-
atic juice from humans or murine models (29–36), we
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Figure 6 MALDI-TOF/MS serum profile (A) and fragments obtained from the feature at m/z 3522.2080 (B).
found no match with the features in sera. This appar-
ent discrepancy may be due to differences in the pro-
teomic techniques used in the different studies, and
in the clinical selection of patients.
By employing the Biomarker Pattern software, we
first generated an algorithm based only on the SELDI-
TOF/MS features. Of the three main splitters selected
(m/z 1526, 1211 and 3519), none matched with the
previously reported discriminant features obtained
using similar protocols (16, 18). One of the reasons
for this discrepancy may be the presence of patients
with type 2 diabetes mellitus in our series. The pres-
ence of diabetics has also been suggested by Honda
et al. (24) to have a potential role in influencing the
classifiers when patients with pancreatic cancer are
studied. The 1526 and 1211 features, the main clas-
sifiers for type 2 diabetes mellitus, might be metabolic
products, proteolytic fragments or peptide hormones
(10, 37). The overall accuracy of the classification
algorithm constructed using SELDI-TOF/MS features
only was about 70%. A comparison was then made
with the well-established marker CA 19-9, which is
widely used in clinical practice for diagnosis, evalua-
tion of therapy and for detecting recurrence (8, 9).
When used alone, this marker had an overall diag-
nostic accuracy of 83%, which was not improved
when the marker was combined with SELDI-TOF/MS
features (76%). Therefore, SELDI-TOF/MS findings did
not reinforce the results obtained with serum CA 19-9
determination alone.
The initial algorithm included patients and healthy
controls, who are not usually included in studies on
the differential diagnosis of pancreatic cancer. In
patients with pancreatic cancer, concomitant patho-
logical conditions such as diabetes mellitus may lead
to diagnostic uncertainty. We, therefore, re-evaluated
SELDI-TOF/MS features together with CA 19-9, con-
sidering only diabetes mellitus patients with pancre-
atic cancer, chronic pancreatitis or type 2 diabetes
mellitus. When considering this cohort of patients,
SELDI-TOF/MS features had a diagnostic advantage
over CA 19-9 alone, allowing the correct classification
of a large percentage of cases (100% type 2 diabetes
mellitus, 76.7% pancreatic cancer, 96.6% chronic pan-
creatitis). However, the distinction made between
pancreatic cancer and chronic pancreatitis was weak-
er than that made between pancreatic cancer and type
2 diabetes mellitus.
Further investigation was done to establish whether
SELDI-TOF/MS features might offer insight on some
aspects correlated with pancreatic cancer, namely
metastases and survival. Only one feature (m/z 3199)
was selected, together with CA 19-9, for differentiat-
ing between pancreatic cancer patients with and with-
out metastases. No correlation was found with CA
19-9 and, among the 219 SELDI-TOF/MS features,
only six were correlated with survival using univariate
analysis. Multivariate analysis confirmed that three
features, those at m/z 1805, 2054 and 2878, were pre-
dictive for pancreatic cancer survival, independent of
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tumor stage. The former and the latter features were
associated with pancreatic cancer (Table 1) and
appear promising tools for future clinical applications.
Finally, using MALDI-TOF/MS, it was possible to
identify the pancreatic cancer-associated ion at m/z
3522.2080 as the deamidated fragment 458–493 of
Multiple Epidermal Growth Factor like domains 6 pre-
cursor. The Epidermal Growth Factor Family mole-
cules are known to have pro-proliferative action (38),
and increased Heparin Binding-EGF like mRNA con-
centrations have already been described in pancreatic
cancer tissue (39). This further supports the idea that
this biomarker has potential diagnostic implications.
In conclusion, SELDI-TOF/MS allowed the identifi-
cation of new peptides in sera. These findings, in
addition to CA 19-9, facilitates the differential diag-
nosis between pancreatic cancer and type 2 diabetes
mellitus. Among the large number of classification
peptides identified following SELDI-TOF/MS, that at
m/z 3519, submitted to MALDI-TOF/MS analysis,
appears to be a member of the epidermal growth
factor like family.
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